Thrombocytopenia, Neonatal Alloimmune clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
open to eligible females ages 18-45
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
at UC Davis
Last updated: